Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management hi...
Charles River Laboratories International (NYSE:CRL) reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earning
Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 2.7% year on ...
Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 2.7% year...
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting results this Wednesday before the bell. Here’s what to look for. Charles River L...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P...
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.
